BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Biotech Beach

  Biocom Urges Senate Committee to Improve Orphan Drug Tax Credit Provision, Eliminate Provision Taxing Stock Options

  The statement can be attributed to Joe Panetta, Biocom’s president and CEO.

  November 14, 2017

   · 

  4 min read
• Drug Development

  Alkermes’ VIVITROL and Value of Medication-Assisted Treatment for Opioid Dependence Featured in Study Sponsored by National Institute on Drug Abuse

  This is the second study published in the past month comparing these two medications and it provides additional evidence supporting the use of VIVITROL as an effective treatment option for patients.

  November 14, 2017

   · 

  12 min read
• 

  Deals

  Cardinal Health Unloads China Biz to Shanghai Pharma in $1.2B Deal

  The transaction is expected to close by the end of Cardinal Health’s fiscal year, subject to closing conditions and regulatory clearances.

  November 14, 2017

   · 

  5 min read
• Genetown

  Sage Therapeutics Prices Public Offering of Common Stock

  The offering is expected to close on or about November 17, 2017, subject to the satisfaction of customary closing conditions.

  November 14, 2017

   · 

  5 min read
• Business

  Abzena Release: Novel Antibodies Against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, With Support From Abzena, Featured in ‘Nature’ Article

  Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, works with Enleofen Bio, to develop first-in-class antibody therapeutics for the treatment of fibrotic human diseases.

  November 14, 2017

   · 

  4 min read
• ITL BioMedical Launches ITL Clinical; a New Brand to Target Hospital and Clinical Markets

  ITL BioMedical is pleased to announce the launch of a new global brand, ITL Clinical, that will feature ITL products that serve the hospital and clinical markets.

  November 14, 2017

   · 

  2 min read
• Dr. Reddy’s Laboratories Announces the Launch of Clofarabine Injection in the U.S. Market

  The Clolar brand and generic had U.S. sales of approximately $53 million MAT for the most recent twelve months ended in September 2017, according to IMS Health.

  November 14, 2017

   · 

  2 min read
• Biotech Beach

  Corvia Medical Announces Enrollment of First Patients in Pivotal Trial of the IASD System II for the Treatment of Heart Failure

  Dr. Sanjiv Shah from Northwestern Memorial Hospital’s Center for Heart Failure at the Bluhm Cardiovascular Institute in Chicago will be presenting on behalf of the investigators, at the Innovative Therapies and Novel Applications session of the Late-Breaking Science program.

  November 14, 2017

   · 

  4 min read
• Business

  Exicure, Inc. Reports Third Quarter 2017 Financial Results and Provides Business Update

  As of September 30, 2017 Exicure had cash and cash equivalents of $22.9 million compared to $19.6 million as of December 31, 2016.

  November 14, 2017

   · 

  10 min read
• Scipio bioscience Announces Its Seed Funding

  A total of €1.2m has been obtained from two European seed funds: Paris, France-based Seventure Partners’ Quadrivium I seed fund and Bonn, Germany-based High-Tech Gründerfonds.

  November 14, 2017

   · 

  5 min read